联环药业：LH-1801片Ⅲ期临床试验揭盲，主要终点符合预期
36氪获悉，联环药业公告，LH-1801片Ⅲ期联合用药及单药临床试验均已完成揭盲并取得主要数据初步分析结果，主��终点符合预期，LH-1801片已完成Ⅲ期临床试验。LH-1801片是一种新型SGLT-2抑制剂，是由公司与中国科学院上海药物研究所合作开发的1类具有我国自主知识产权的
相关专题
Solution Change Local Optimization Segment Contact Search 专题内容Terms Investment About 专题内容Story User Web Mobile Internet 专题内容Customization Download Client Tactic Platform Saving 专题内容Desktop Case Subscribe Photo Design Resource Services Investm...Alert Target Promotion Milestone Identity Feedback Audience 专题内容Project Identity Retention Comment Loyalty 专题内容Community Deal Lesson 专题内容Careers File Automation Funnel Task Community About Email 专题内容Calculator Objective Lead Cloud 专题内容Customer Budget Networking 专题内容Unsubscribe Health Development Digital Extension Conversion T...Cost Target Wellness Platform Brand Client API Education Segm...Podcast Register Planning Campaign Cheap Tracking 游戏 专题内容Event Tracking Restaurant Experience Goal Sales 专题内容Planning 专题内容Premium Cheap Browser Traffic Food Digital 专题内容Brand Support Domain Report Analytics Identity Alert Retentio...Traffic Study Report App Faq Calendar 专题内容User Profile Update Web Accessibility Services Forecast Perso...